UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) November 14, 2018 (November 7, 2018)

 

Wize Pharma, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   000-52545   88-0445167
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

24 Hanagar Street, Hod Hasharon, Israel   4527708
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code:   +(972) 72-260-0536

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

The information provided in response to Item 5.02 of this report is incorporated by reference into this Item 1.01.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointments and Resignations

 

On November 7, 2018, Noam Danenberg was appointed to the Board of Directors (the “ Board ) of Wize Pharma, Inc. (the " Company ") and as Chairman of the Board. Also on November 7, 2018 Mr. Danenberg resigned as the Chief Operating Officer of the Company. Mr. Danenberg’s decision to resign was not as a result of any disputes with the Company.

 

On November 7, 2018, Ron Mayron resigned from the Board and as Chairman of the Board, effective upon Mr. Danenberg’s appointment. Mr. Mayron’s decision to resign was not as a result of any disputes with the Company. Mr. Mayron is expected to continue to serve the Company as a part-time consultant.

 

Noam Danenberg served as our Chief Operating Officer from November 15, 2017 until his resignation on November 7, 2018. He has served as a strategic advisor to Wize Pharma Ltd. (“ Wize Israel ”), the Company’s wholly owned subsidiary, since April 2015. Mr. Danenberg co-founded Panmed Inc. in January 2014, a company in the field of repositioning drugs activities. Since 2000, Mr. Danenberg has provided private investment consulting services to numerous private and public companies through his wholly owned company, N. Danenberg Holding (2000) Ltd. From May 2014 to January 2015, Mr. Danenberg served as a director of Go.D.M. Investments Ltd. (TASE: GODM). From 2000 to 2012, Mr. Danenberg served as an investment advisor at International Software Consulting Limited and from 2004 to 2008 he served as the Chairman and CEO of Fitracks Inc. From 2006 to 2012, he also served as the Chairman of the Board of Hawk Medical Technologies Ltd. Mr. Danenberg holds a B.B.A. in Computer Science from the European University in Antwerp, Belgium and an M.B.A. from the Boston University Brussels Graduate Center.

 

There are no understandings or arrangements between Mr. Danenberg and any other person pursuant to which Mr. Danenberg was selected as a director. There are no family relationships between Mr. Danenberg and any director or other executive officer of the Company, and he does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. The Company expects to pay Mr. Danenberg and related entities an aggregate of approximately $195,000 for the fiscal year ending December 31, 2018 pursuant to the Original Agreement, as amended (as defined below).

 

Consulting Agreements

 

As previously disclosed in the Company’s 8-K filed with the SEC on August 22, 2018, on August 20, 2018, Wize Israel entered into a restated consulting services agreement (the “ Original Agreement ”) with Mr. Danenberg and N. Danenberg Holdings (2000) Ltd., an Israeli company affiliated with Mr. Danenberg (the “ Consulting Company ”). On November 7, 2018, Wize Israel, Mr. Danenberg and the Consulting Company entered into amendment No.1 to the Original Agreement (the “ Amendment ”), through which the parties amended the Original Agreement to remove references to Mr. Danenberg’s service as Chief Operating Officer. The compensation and other material terms of the Original Agreement were not revised.

 

On November 7, 2018, the Company and Wize Israel entered into a consulting agreement (the “ Consulting Agreement ”) with Ron Med Ltd, an Israeli company affiliated with Mr. Mayron (the “ Consultant ”), pursuant to which Ron Med shall serve as a strategic advisor to the Company's senior management and Board. The Consultant shall receive a monthly compensation of NIS 20,000 (approximately $5,415). The Consulting Agreement shall have a term of one year (the “ Initial Term ”) and shall be renewed for additional one year periods. The Consulting Agreement may be terminated by either party following the Initial Term.

 

 

The foregoing description of the Amendment and of the Consulting Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to the Amendment and the Consulting Agreement, which are filed herewith as Exhibit 10.1 and 10.2, and are incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

10.1 Amendment No. 1 to Consulting Services Agreement
10.2 Consulting Agreement

1
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Wize Pharma, Inc.
     
  By: /s/ Or Eisenberg
  Name: Or Eisenberg
Date: November 14, 2018 Title: Chief Executive Officer

 

2

 

Exhibit 10.1

 

Amendment No. 1

to
RESTATED CONSULTING AGREEMENT

 

This Amendment No. 1 (the “Amendment”) to Restated Consulting Agreement dated April 29, 2018 (the “Original Agreement”) is effective November 7, 2018 (the “Amendment Effective Date”) and is by and among Wize Pharma Ltd. (Registration Number 520033259), a limited liability company operating under the laws of Israel with offices at Hanagar 24, PO Box 6653 Hod Hasharon, Israel (the “Company”) and N. Danenberg Holdings (2000) Ltd. (Registration Number 512950981), a limited liability company operating under the laws of Israel having its principal place of business at Borochov 4, Hod- Hasharon, (the “Consulting Company”) through Noam Danenberg I.D. 27868272, an individual residing at Borochov 4, Hod Hasharon (“Mr. Danenberg”).

 

WHEREAS:

 

A.      As of the Amendment Effective Date, Mr. Danenberg has resigned as Chief Operating Officer of the Company’s sole stockholder, Wize Pharma, Inc. (“Wize”) and has been elected to the Board of Directors of Wize (the “Board”) and appointed Chairman of the Board;
   
B.       The Parties desire to amend the Original Agreement accordingly; and
   
C.      Except as set forth in this Amendment, all other terms and conditions of the Original Agreement shall remain in full force and effect.

 

WHEREFORE, IT IS HEREBY AGREED as follows:

 

1.  The second and third paragraphs of Section 1.1 of the Original Agreement shall be amended and restated in their entirety as set forth below:

 

In this regard, the Consulting Company through Mr. Danenberg exclusively shall provide the Company and any of its Affiliates with general strategic consulting services, as required in the field of business development and raising funds, all as shall be required from time to time by the Company (the “ Consulting Services ” or the “ Services ”).

 

While acting as a representative of Consulting Company, Mr. Danenberg shall report to and receive instructions from the Board of Directors of the Company from time to time.

 

2.   Except as set forth in this Amendment, all other terms and conditions of the Original Agreement shall remain in full force and effect.

 

[signature page follows immediately]

 

 

 

 

IN WITNESS WHEREOF, the Parties hereto have executed the Agreement effective as of the date first above written.

 

COMPANY:      
         
WIZE PHARMA LTD.      
         
Signature:  /s/ Yossi Keret   Signature:  /s/ Or Eisenberg
Name: Yossi Keret   Name: Or Eisenberg
Title: Director   Title: Director

 

CONSULTING PARTIES:  
     
N. DANENBERG HOLDINGS (2000) LTD.  
     
Signature:  /s/ Noam Danenberg  
Name: Noam Danenberg  
Title:    
     
Signature:  /s/ Noam Danenberg  
Name: Noam Danenberg, in his  
  Individual capacity  

 

 

 

 

Exhibit 10.2

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “ Agreement ”) is dated as of November 7, 2018, by and between WIZE PHARMA INC and/or WIZE PHARMA, LTD . (“ Company ”), with a principal place of business and mailing address at 24 Hanagar st. PO Box 6653, Hod Hasharon, Israel; and Ron Med Ltd , an Israeli company (“ Consultant ”), with address for notices at: 22a HaOranim St. Hod Hasharon, Israel.

 

WHEREAS, the Company wishes to obtain from the Consultant the Services pursuant to the terms and conditions of this Agreement; and

 

WHEREAS, the Consultant wishes to provide the Company with the Services pursuant to the terms and conditions of this Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

 

1. The Services . During the term of this Agreement, the Consultant agrees, when requested by the Company, to act as a consultant and render to the Company the services set forth in Exhibit A hereto (the “ Services ”).

 

2. Supervision . While acting as a consultant for the Company, the Consultant shall be under the supervision of the Company’s CEO (or a person designated thereby).

 

3. Term. The contractual relationship pursuant to this Agreement will commence on the date hereof (“ Commencement Date ”) and shall expire no less than one year and shall be renewed for additional one year periods. Notwithstanding the foregoing, each party may, only after one year following the Commencement Date, terminate this Agreement (A) upon 60 days prior written notice or (B) immediately by provision of a written notice, in any of the following circumstances: (i) in the case of Company - commission of a criminal offence, breach of trust or similar action committed by Consultant adverse to the Company; (ii) in the case of Company – material breach of any of the Consultant’s undertakings as set forth in this Agreement; or (iii) in the case of Consultant – material breach of any of the Company’s undertakings as set forth in this Agreement.

 

4. Compensation – The Consultant shall be entitled to receive consideration for the Services as set forth in Exhibit A hereto. The consideration payable (including issued) hereunder includes all taxes, levies and charges however designated and levied by any state, local, or government agency (including VAT). Consultant shall have sole responsibility for the payment of all of such taxes, levies and charges and Company may deduct and withhold from any consideration made hereunder all sums which it is required to deduct or withhold pursuant to any applicable laws.

 

5. Confidentiality and Intellectual Property Rights.

 

5.1 The Consultant agrees during the term of this Agreement and thereafter that it will hold the Proprietary Information of the Company (for purposes hereof, including any of its affiliates) in confidence and will not use Proprietary Information in any manner or for any purpose other than providing the Company with the Services. By way of illustration but not limitation, “ Proprietary Information ” includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques; and (b) information regarding plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers; and (c) information regarding the skills and compensation of other employees of Company.

 

  1  

 

 

5.2 The Consultant understands that Company has received and will in the future receive from third parties confidential or proprietary information (“ Third Party Information ”). Consultant agrees to hold Third Party Information in confidence and not to disclose to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or to use, except in connection with Consultant provision of Services for Company, Third Party Information unless authorized in writing by the Company.

 

5.3 Consultant irrevocably assigns to Company all right, title and interest worldwide in and to the Company Work Product and all applicable intellectual property rights related to the Company Work Product and agrees not to challenge the validity of Company’s ownership in the Company Work Product. As used in this Agreement, the term “Company Work Product ” means any Proprietary Information that is solely or jointly conceived, made, reduced to practice, or learned by Consultant in the course of any provision of Services.

 

5.4 Consultant agrees to cooperate with Company or its designee(s), both during and after the termination of this Agreement, to carry out the purpose of this Section 5.

 

5.5 Upon termination of the Agreement or earlier as requested by Company, Consultant will deliver to Company any and all material containing any Company Work Product, Third Party Information or Proprietary Information of Company.

 

6. Representations and Warranties. C onsultant hereby represents and warrants and acknowledges (i) that Consultant has full right and power to enter into and perform this Agreement in good faith without the consent of any third party; (ii) that during the term of this Agreement not to accept any work or enter into any contract or understanding or accept an obligation, inconsistent with Consultant’s obligations under this Agreement or the scope of the Services; Data and software stored on magnetic and other media that cannot be returned shall be destroyed by Consultant together with all copies thereof; and (iii) in connection with the stock options exercisable inot shares of common stock of the Company issuable hereunder as consideration, Consultant understands that the investment in such securities is speculative in nature and involves a high degree of risk, and she or he is able to bear the economic risks of an investment therein.

 

7. Independent Consultant Relationship; Etc . Consultant’s relationship with Company will be that of an independent consultant and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Consultant is not the agent of Company and is not authorized to make any representation, contract, or commitment on behalf of Company. Consultant will not be entitled to any of the benefits that Company may make available to its employees, such as group insurance, profit-sharing, or retirement benefits.

 

8. General Provisions.

 

8.1 Severability . In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.

 

  2  

 

 

8.2 Governing Law; Venue .

 

8.2.1 This Agreement, including the validity, interpretation, or performance of this Agreement and any of its terms or provisions, and the rights and obligations of the parties under this Agreement shall be exclusively governed by, construed and interpreted in accordance with the laws of the State of Israel, without regards to the choice of law provisions thereof.

 

8.2.2 In the event of any dispute or claim in connection with this Agreement, then either party may submit the dispute or claim to (and all such disputes and claims shall be resolved solely by) the competent courts in Tel Aviv, Israel.

 

8.2.3 Each of the parties further agrees that notice as provided in Section 8.6 hereof shall, without derogating from any other proper means of serving process under applicable law, constitute sufficient service of process and the parties further waive any argument that such service is insufficient.

 

8.3 No Assignment. This Agreement may not be assigned by the Consultant without Company’s prior and written consent, and any such attempted assignment shall be void and of no effect.

 

8.4 Waiver . No waiver by Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement shall be construed as a waiver of any other right.

 

8.5 Entire Agreement . This Agreement, including Exhibit A hereto, is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged

 

8.6 Notices. All communications under this Agreement shall be in writing and shall be delivered by hand, facsimile or mailed by registered or certified mail, postage prepaid, or electronic email to the address of such party in the preamble to this Agreement or at such other address as such party may have furnished to the other party in writing. Any notice so addressed shall be deemed to be given: if delivered by hand or by facsimile or email, on the first business day following the date of such delivery; if mailed by courier, on the first business day following the date of such mailing; and if mailed by registered or certified mail, on the third business day after the date of such mailing.

 

8.7 Survival . The following provisions shall survive in good faith for 24 month termination of this Agreement: Sections 3, 5, 6, 7 and 8.

 

8.8 Section Headings . The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute a part thereof.

 

8.9 Construction . The words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The use of the word “or” shall not be exclusive unless expressly indicated otherwise. Any reference to “days” means calendar days unless Business Days are expressly specified. The word “party” shall, unless the context otherwise requires, be construed to mean a party to this Agreement. Any reference to a party to this Agreement or any other agreement or document contemplated hereby shall include such party’s successors and permitted assigns. The headings herein are for convenience of reference only, do not constitute part of this Agreement, and shall not be deemed to limit or otherwise affect any of the provisions hereof. All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.” The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied in the construction or interpretation of this Agreement.

  

[signature page follows]

 

  3  

 

 

IN WITNESS WHEREOF, the parties have executed this Consulting Agreement on the date first written above.

 

Ron Med Ltd  
   
By: /s/ Ron Mayron  
Name: Ron Mayron  
Title:    
   
WIZE PHARMA, INC .  
   
By: /s/ Or Eisenberg  
Name:  Or Eisenberg  
Title: Acting CEO  
   
WIZE PHARMA, LTD .  
   
By: /s/ Or Eisenberg  
Name: Or Eisenberg  
Title: Director  

 

  4  

 

 

EXHIBIT A
SERVICES AND CONSIDERATION

 

- Position: Strategic advisor to the Company’s senior management and Board of Directors

  

- Scope: Expected to be available for strategic meetings/sessions/calls with management on a weekly basis and for all board of directors or relevant committee meetings

  

- Compensation: NIS 20,000 (including VAT if applicable) per full month (“ the monthly payment ”), against a tax invoice in accordance with the law which the Consultant shall submit to the Company. The monthly payment shall be paid by the Company (either Wize Pharma Inc. or Wize Pharma Ltd., at Company’s discretion) not later than 10 days from the date of issue of an undisputed tax invoice. The Consultant undertakess to submit the tax invoices to the Company not later than the 5th day of each calendar month for the preceding month.

  

- Consultant will not be reimbursed for any expenses incurred in connection with the performance of the Services, unless otherwise agreed in writing by the Company and in advance.

 

  5